Today we speak with Professor Jann-Yuan Wang, a clinician and researcher in Taiwan, about his work in latent tuberculosis. Professor Wang speaks about his experience using 3HP and the challenges of systemic drug reactions. Professor Wang talks about his research into predicting which patients will experience systemic drug reactions based on research algorithms of clinical characteristics, plasma drug levels and transcriptomic factors.
REFERENCES:
1) Lee, Ming‐Chia, et al. "Isoniazid level and flu‐like symptoms during rifapentine‐based tuberculosis preventive therapy: A population pharmacokinetic analysis." British journal of clinical pharmacology (2022).
2) Peng, Tzu-Rong, et al. "Advantages of short-course rifamycin-based regimens for latent tuberculosis infection: an updated network meta-analysis." Journal of Global Antimicrobial Resistance 29 (2022): 378-385.
3) Huang, Hung-Ling, et al. "Whole-blood 3-gene Signature as a Decision Aid for Rifapentine-based TB Preventive Therapy." Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America (2022).
4) Huang, Hung-Ling, et al. "Impact of age on outcome of rifapentine-based weekly therapy for latent tuberculosis infection." Clinical Infectious Diseases 73.5 (2021): e1064-e1071.
5) Lee, Meng-Rui, et al. "Isoniazid concentration and NAT2 genotype predict risk of systemic drug reactions during 3HP for LTBI." Journal of clinical medicine 8.6 (2019): 812.
6) Sun, Hsin-Yun, et al. "Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan." Tuberculosis 111 (2018): 121-126.
7) Lee, Meng-Rui, et al. "Plasma Concentration of Isoniazid and Single-Nucleotide Polymorphisms of N-Acetyltransferase 2 Predict Risk of Systemic Drug Reactions During Weekly Rifapentine and Isoniazid Therapy for Latent Tuberculosis Infection: A Prospective Observational Cohort Study." Available at SSRN 3297903 (2018).
Today we speak with Professor Jann-Yuan Wang, a clinician and researcher in Taiwan, about his work in latent tuberculosis. Professor Wang speaks about his experience using 3HP and the challenges of systemic drug reactions. Professor Wang talks about his research into predicting which patients will experience systemic drug reactions based on research algorithms of clinical characteristics, plasma drug levels and transcriptomic factors.
REFERENCES:
1) Lee, Ming‐Chia, et al. "Isoniazid level and flu‐like symptoms during rifapentine‐based tuberculosis preventive therapy: A population pharmacokinetic analysis." British journal of clinical pharmacology (2022).
2) Peng, Tzu-Rong, et al. "Advantages of short-course rifamycin-based regimens for latent tuberculosis infection: an updated network meta-analysis." Journal of Global Antimicrobial Resistance 29 (2022): 378-385.
3) Huang, Hung-Ling, et al. "Whole-blood 3-gene Signature as a Decision Aid for Rifapentine-based TB Preventive Therapy." Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America (2022).
4) Huang, Hung-Ling, et al. "Impact of age on outcome of rifapentine-based weekly therapy for latent tuberculosis infection." Clinical Infectious Diseases 73.5 (2021): e1064-e1071.
5) Lee, Meng-Rui, et al. "Isoniazid concentration and NAT2 genotype predict risk of systemic drug reactions during 3HP for LTBI." Journal of clinical medicine 8.6 (2019): 812.
6) Sun, Hsin-Yun, et al. "Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan." Tuberculosis 111 (2018): 121-126.
7) Lee, Meng-Rui, et al. "Plasma Concentration of Isoniazid and Single-Nucleotide Polymorphisms of N-Acetyltransferase 2 Predict Risk of Systemic Drug Reactions During Weekly Rifapentine and Isoniazid Therapy for Latent Tuberculosis Infection: A Prospective Observational Cohort Study." Available at SSRN 3297903 (2018).